文献速递乳腺MR

基于MRI的影像组学列线图鉴别乳腺导管原位癌伴微浸润与导管原位癌

An MRI-Based Radiomics Nomogram to Distinguish Ductal Carcinoma In Situ with Microinvasion From Ductal Carcinoma In Situ of Breast Cancer.
PubMed 文献 · Acad Radiol · 2023-05-20

本研究纳入2019年3月至2022年11月本机构的140例乳腺MR图像,随机分为训练集97例和测试集43例,构建基于DCE-MRI的影像组学列线图以鉴别导管原位癌伴微浸润(DCISM)与纯导管原位癌(DCIS)。列线图在训练集AUC为0.911(95%CI 0.848-0.974),测试集AUC为0.882(95%CI 0.764-0.999),优于临床因素模型。

要点

  • 基于DCE-MRI的影像组学列线图在训练集鉴别DCISM与DCIS的AUC为0.911,测试集为0.882。
  • 影像组学特征联合独立临床危险因素的列线图,判别效能优于单纯临床因素模型。
  • 决策曲线显示列线图模型具有良好的临床实用性。

核心结论

  • 所提出的基于无创MRI的影像组学列线图模型在鉴别DCISM与DCIS方面表现出良好性能。

研究设计与样本

  • 回顾性研究,纳入本机构2019年3月至2022年11月的140例乳腺MR图像,随机分为训练集97例和测试集43例,各集进一步分为DCIS和DCISM亚组;采用多因素logistic回归筛选独立临床危险因素建立临床模型,采用最小绝对收缩和选择算子筛选最优影像组学特征并构建影像组学标签,整合影像组学标签与独立危险因素构建列线图模型,通过校准曲线和决策曲线评估判别效能。

诊断标准与关键数值

  • 共筛选6个特征构建鉴别DCISM与DCIS的影像组学标签;影像组学标签和列线图模型在训练集的AUC分别为0.815(95%CI 0.703-0.926)和0.911(95%CI 0.848-0.974),在测试集的AUC分别为0.830(95%CI 0.672-0.989)和0.882(95%CI 0.764-0.999);临床因素模型在训练集AUC为0.672(95%CI 0.544-0.801),测试集AUC为0.717(95%CI 0.527-0.907)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: Accurate preoperative differentiation between ductal carcinoma in situ with microinvasion (DCISM) and ductal carcinoma in situ (DCIS) could facilitate treatment optimization and individualized risk assessment. The present study aims to build and validate a radiomics nomogram based on dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) that could distinguish DCISM from pure DCIS breast cancer.

MATERIALS AND METHODS: MR images of 140 patients obtained between March 2019 and November 2022 at our institution were included. Patients were randomly divided into a training (n = 97) and a test set (n = 43). Patients in both sets were further split into DCIS and DCISM subgroups. The independent clinical risk factors were selected by multivariate logistic regression to establish the clinical model. The optimal radiomics features were chosen by the least absolute shrinkage and selection operator, and a radiomics signature was built. The nomogram model was constructed by integrating the radiomics signature and independent risk factors. The discrimination efficacy of our nomogram was assessed by using calibration and decision curves.

RESULTS: Six features were selected to construct the radiomics signature for distinguishing DCISM from DCIS. The radiomics signature and nomogram model exhibited better calibration and validation performance in the training (AUC 0.815, 0.911, 95% confidence interval [CI], 0.703-0.926, 0.848-0.974) and test (AUC 0.830, 0.882, 95% CI, 0.672-0.989, 0.764-0.999) sets than in the clinical factor model (AUC 0.672, 0.717, 95% CI, 0.544-0.801, 0.527-0.907). The decision curve also demonstrated that the nomogram model exhibited good clinical utility.

CONCLUSION: The proposed noninvasive MRI-based radiomics nomogram model showed good performance in distinguishing DCISM from DCIS.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Wu, Lin, Wang, et al. An MRI-Based Radiomics Nomogram to Distinguish Ductal Carcinoma In Situ with Microinvasion From Ductal Carcinoma In Situ of Breast Cancer. Acad Radiol. 2023. PMID: 37211478. doi:10.1016/j.acra.2023.03.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。